We strive to be a global biopharma leader whose mission is

to develop innovative, life-changing medicine


BTK & FLT3 dual inhibitor
  • Indication
    Acute myelogenous leukemia (AML), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and non-Hodgkin lymphoma (NHL)
  • Development stage
    • U.S. Phase 1 clinical study for AML (monotherapy) in progress
    • Additional Phase 1 clinical studies in development for CLL, SLL, NHL in the U.S.

BTK & FLT3 dual inhibitor

CG-806's competitive advantage
  1. 01

    Blocks signal transmission by specifically binding to FLT3 and BTK and minimizes off-target effects

  2. 02

    Inhibition of FLT3 and BTK within cancer is considered to be superior to competitors based on pre-clinical studies

  3. 03

    Oral formulation. Non-clinical GLP-Tox trial proves safety in clinical trials in patients

  4. 04

    FDA orphan drug designation: AML

FLT3 (Fms Like Tyrosine Kinase 3), BTK (Bruton’s Tyrosine Kinase)
  • FLT3

    Tyrosine kinase receptors are important for the development of B and T cells. Excessive activity due to the FLT3 mutation was observed in 1/3 of patients with acute myelogenous leukemia.

  • BTK

    A component of B cell receptors essential for B cell maturation, survival, and proliferation.
    BTK overexpression and mutation are observed in various B cell carcinomas.